fda warning compounding semaglutide september 2025 Diabetes advocacy group discourages use of compounded GLP-1 drugs August 11, 2025: The FDA

Check with your prescription drug plan about out-of-pocket costs like deductibles, copays, or coinsurance costs

[1] [2] In that trial, diarrhoea was reported in a meaningful proportion of participants, with rates generally higher at elevated doses and during escalation periods

however, those who persisted with the medication coverage experienced weight losses comparable with those shown in corresponding clinical trials. And in a paper published in 2023, researchers found that while significant weight loss was achievable with GLP-1s among type 2 diabetes patients, the average weight reduction was relatively modest, 2.2% after 72 weeks of being on the medications

H.AgerberthB.OdebergJ.BergmanT.OlssonB.SalcedoR

The stock is a no-brainer buy